Provided is a compound with strong human S1P2 antagonistic activity in order to develop drug products that are useful for treating S1P2 mediated disorders such as disorders that cause constriction of blood vessels, fibrosing disease, respiratory disease, and the like. The compound expressed by general formula (I) (in formula, all symbols are as described in the specification) has strong human S1P2 antagonistic activity by introducing a halogen atom or a haloalkyl group and a phenoxy group to a specific substitution site, and therefore can provide a therapeutic agent for S1P2 mediated disorders such as disorders that cause constriction of blood vessels, fibrosing disease, respiratory disease, and the like.
